The industry’s focus is on living organisms, and the strict enforced standards make it an distinct consideration for business leaders. These characteristics make the industry an ideal platform for innovation. They have resulted in major breakthroughs in biofuels, agricultural yields and life-saving pharmaceuticals.

Start-up biotech companies have many options when it comes down to revenue generation strategies, with most opting for a technology-based partnership or an asset creation and out-licensing approach. Technology partnering can result in faster revenue and lower financial risk, while assets creation and outlicensing strategies can generate significantly greater returns. A increasing number of biotechs at the research stage use an approach that blends both strategies.

The people who choose an approach to development that is oriented towards product will be successful commercially when they get their pipeline to the right stage and then attract a major pharma partner or an investor with deep pockets. This could be a costly venture. It is essential to weigh the pros and cons of taking advantage of outside resources and the proper scientific decision-making regarding the development of home-grown products.

The “platform” model is an alternative alternative to generate revenue. It is less costly than product-oriented research, but comes with a high risk. In this model, a biotech owns and develops its platform technology prior to collaboration https://genotec-frankfurt.de/bio-pharmazeutika-werden-zu-einer-anerkannten-form-der-alternativmedizin/ with big pharma firms to create a portfolio drug discovery projects that target specific diseases (i.e., disease that is x within biology and y). Advinus Therapeutics, among others have embraced this model.